logo

Sangamo Biosciences Inc (SGMO)



Trade SGMO now with
  Date
  Headline
1/22/2019 4:06:52 PM Sangamo Therapeutics Appoints Adrian Woolfson As EVP Of Research And Development
12/17/2018 8:12:39 AM Sangamo Announces Treatment Of The First Patient In Phase 1/2 Clinical Trial Evaluating SB-FIX
12/3/2018 7:12:58 AM Sangamo Therapeutics Completes Acquisition Of TxCell
10/1/2018 8:12:02 AM Sangamo And TxCell Announce Completion Of Acquisition By Sangamo Of Majority Of TxCell Ordinary Shares
9/5/2018 8:16:52 AM Sangamo Announces 16 Week Results Including Reductions In Glycosaminoglycans In Phase 1/2 Trial Evaluating SB-913
7/23/2018 7:04:35 AM Sangamo Announces Treatment Of First Patient In Phase 1/2 Clinical Trial Of SB-318 For MPS I
7/23/2018 2:33:52 AM Sangamo Therapeutics To Acquire TxCell At EUR 2.58 Per Share In Cash, Or EUR 72 Mln
7/13/2018 4:20:37 PM Sangamo Therapeutics Announces Resignation Of Michael Holmes As SVP And Chief Technology Officer
6/28/2018 4:10:42 PM Sangamo Therapeutics Appoints Karen Smith To Its Board Of Directors
6/4/2018 8:15:47 AM Sangamo : U.K. Authorizes For Enrollment Of Subjects Into Ongoing Phase 1/2 Clinical Trials Evaluating SB-318 And SB-913
5/21/2018 3:51:48 PM Wedbush Is Lowering Sangamo Biosciences Inc (SGMO) FY19 Estimate To -0.14 From 0.04
5/21/2018 3:51:31 PM Wedbush Is Cutting Sangamo Biosciences Inc (SGMO) Q3 19 Estimate To -0.04 From 0.01
5/21/2018 3:51:22 PM Wedbush Is Lowering Sangamo Biosciences Inc (SGMO) Q2 19 Estimate To -0.04 From 0.01
5/21/2018 3:51:06 PM Wedbush Is Cutting Sangamo Biosciences Inc (SGMO) Q1 19 Estimate To -0.02 From 0.03
5/21/2018 3:50:57 PM Wedbush Is Cutting Sangamo Biosciences Inc (SGMO) Q4 18 Estimate To -0.02 From 0.03